With every passing day, the number of cardiac patients are escalating globally. Mitral regurgitation is one of such serious heart ailments that take thousands of lives every year. As per expert reports, over 4 million patients are suffering from the disease counting the western countries only.
To treat this severe cardiac disorder, Paris-based medtech HighLife has developed path-breaking transcatheter mitral valve replacement (TMVR) system. Now, the startup has just raised €32 million in a funding round to further develop its medical device.